Holen Sie sich die Stockscreener-App
78.68
4.98%
3.73
Handel nachbörslich:
76.44
-2.24
-2.85%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Reports Clinical Findings for P - GuruFocus
Arrowhead presents plozasiran data on renal, hepatic impairment By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - Arrowhead Pharmaceuticals, Inc.
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Insider Monkey
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Barchart.com
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
What is Zacks Research's Estimate for ARWR FY2026 Earnings? - MarketBeat
Baader Bank Aktiengesellschaft Purchases Shares of 14,194 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Insider Sell: Hongbo Lu Sells Shares of Arrowhead Pharmaceuticals Inc (ARWR) - GuruFocus
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 through May-14-2026 - marketscreener.com
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock - MarketBeat
Arrowhead director Lu Hongbo sells $228,333 of common stock - Investing.com
Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan - Stock Titan
Arrowhead Pharmaceuticals, Inc.Common Stock (NQ: ARWR - FinancialContent
What is HC Wainwright's Forecast for ARWR Q3 Earnings? - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
ARWR Maintained by Bernstein -- Price Target Raised to $46.00 - GuruFocus
Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00 - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 - Investing.com
HC Wainwright Issues Optimistic Outlook for ARWR Earnings - MarketBeat
ARWR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum - Yahoo Finance
[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived (NASDAQ:ARWR) - Seeking Alpha
Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation - MSN
Arrowhead Pharmaceuticals Jumps 7.9% After RBC Capital Maintains Outperform - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Discipline and Rules-Based Execution in ARWR Response - Stock Traders Daily
Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge - Sahm
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E - Sahm
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 - MSN
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets - TipRanks
ARWR Maintained by RBC Capital -- Price Target Raised to $87.00 - GuruFocus
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $87 - Moomoo
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating - marketscreener.com
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - BioSpace
Arrowhead Pharma earnings up next: First Redemplo sales in focus - Investing.com
Arrowhead Pharmaceuticals (ARWR) Reports Strong Progress and Fut - GuruFocus
EDGAR Filing Documents for 0001628280-24-003492 - SEC.gov
ViaSat, Arrowhead Pharmaceuticals, and Coherent Corp. Lead High-Return Stocks - Markets Mojo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):